This review highlights the role of age-related arterial stiffening and central hemodynamics in the pathophysiology of chronic cardiorenal disease, particularly HFpEF and nephrosclerosis.
Highlights potential mechanisms in HFpEF and nephrosclerosis; leaves open whether stiffness-targeted therapies alter cardiorenal outcomes.
As patients with chronic kidney disease (CKD) and chronic heart failure (CHF) increase, there is concern about a future heart failure pandemic. Deterioration of renal function is an independent prognostic factor for CHF after decongestion. Interactions between renal disease and cardiac disease are increasing, including nephrosclerosis and heart failure with preserved ejection fraction (HFpEF), which are both derived from augmentation of central pulse pressure by age-related arterial stiffening. Thus, it is necessary to treat multiple underlying diseases of cardiorenal syndrome simultaneously. However, an effective therapeutic strategy for HFpEF has not been established. This review reconsiders the pathophysiology of chronic cardiorenal disease related to arterial stiffening from the viewpoint of central hemodynamics and explores treatment options.
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: